BioLite, Inc.
The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression.
Eligibility Criteria * 21 to 85 Years of age * Diagnosis of Stage I, II or III cancer * Histologically-proven malignancy * Receiving or within one year of having received cancer treatment with radiation and/or chemotherapy * Montgomery and Åsberg Depression Rating Scale (MADRS) ≥ 20 (moderate to severe depressive symptoms) * Duration of depressive symptoms ≥ 2 weeks by patient report. * No active/acute suicidality requiring immediate care or psychiatric hospitalization * Sufficient English language proficiency to complete all assessments without assistance * Able to swallow pills * No severe…
PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.